Wilmington PharmaTech, a research and manufacturing organization, will invest $18 million for a new facility in Newark, DE and almost quadruple in size from 37 full-time employees to 139.
“This marks the next wave of growth, positioning Wilmington PharmaTech as the leader in new drug manufacturing in the US,” said Hui-Yin Harry Li, Ph.D., President and CEO of Wilmington PharmaTech.
PharmaTech requested a $300,400 performance-based grant and $360,000 grant for assistance with capital costs, according to Delaware Prosperity Partnership, to focus on the company’s growth.
“Wilmington PharmaTech’s expansion shows Delaware’s distinctive strength in supporting biotechnology and pharmaceutical start-up companies and builds on a foundation that began more than 200 years ago with the DuPont Company,” said Governor John Carney. “We remain committed to supporting job growth throughout Delaware.”
In the past six years, Wilmington PharmaTech has seen significant growth. The Northern Delaware community has become the home to multiple PharmaTech locations, making it a premier life sciences and research area, attracting more businesses to the region.